Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,173 questions in 89 reviews · Neuromuscular
current versionsNo studies 302 · 25.7%Ungraded 119 · 10.1%Very low 267 · 22.8%Low 239 · 20.4%Moderate 177 · 15.1%High 69 · 5.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Non‐invasive ventilation vs standard care Survival · people with ALS Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease (2017) · Cochrane | no estimate extracted | 1 study · 41 participants | Moderate |
Non‐invasive ventilation vs standard care Quality of life (SF‐36 MCS) · people with ALS Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease (2017) · Cochrane | no estimate extracted | 1 study · 41 participants | Low |
Non‐invasive ventilation vs standard care Quality of life (SF‐36 PCS) · people with ALS Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Non‐invasive ventilation vs standard care Quality of life (SAQLI) · people with ALS Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease (2017) · Cochrane | no estimate extracted | 1 study · 41 participants | Low |
Non‐invasive ventilation vs standard care Adverse events (not reported) · people with ALS Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Survival at 1 year Estimated survival at 1 year based on trials of 6 and 9 months' duration · people with ALS/MND Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease (2017) · Cochrane | no estimate extracted | 2 studies · 355 participants | High |
Intervention NR Rate of decline in MVIC Expressed as arm megascore1 · people with ALS/MND Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease (2017) · Cochrane | no estimate extracted | 2 studies · 345 participants | High |
Intervention NR Rate of decline of % predicted FVC · people with ALS/MND Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease (2017) · Cochrane | no estimate extracted | 2 studies · 274 participants | High |
Intervention NR Rate of decline (per month) of functional rating scale (over a period of 9 months) Measured by ALSFRS‐R · people with ALS/MND Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease (2017) · Cochrane | no estimate extracted | 1 study · 128 participants | Moderate |
Intervention NR Health‐related quality of life Short Form 12 Health Survey (SF‐12) · people with ALS/MND Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease (2017) · Cochrane | no estimate extracted | 1 study · 128 participants | Moderate |
Intervention NR Adverse events · people with ALS/MND Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease (2017) · Cochrane | no estimate extracted | 2 studies · 353 participants | High |
Oxcarbazepine vs placebo Reduction in participant‐reported pain scores by at least 50% from the baseline VAS · people with painful diabetic neuropathy Oxcarbazepine for neuropathic pain (2017) · Cochrane | RR 1.91 [1.08, 3.39] | 1 study · 146 participants | Very low |
Oxcarbazepine vs placebo Reduction in participant‐reported pain scores by at least 30% from the baseline VAS · people with painful diabetic neuropathy Oxcarbazepine for neuropathic pain (2017) · Cochrane | RR 1.57 [1.01, 2.44] | 1 study · 146 participants | Very low |
Oxcarbazepine vs placebo Participants' global impression of their change in pain Participant's global assessment of therapeutic effect, 'much' or 'very much' · people with painful diabetic neuropathy Oxcarbazepine for neuropathic pain (2017) · Cochrane | RR 1.46 [1.13, 1.88] | 2 studies · 493 participants | Very low |
Oxcarbazepine vs placebo Serious adverse effects · people with painful diabetic neuropathy Oxcarbazepine for neuropathic pain (2017) · Cochrane | RR 3.65 [1.45, 9.2] | 3 studies · 634 participants | Moderate |
Low‐level laser therapy vs placebo Overall improvement in CTS: SSS: short term (< 3 months) Scale from: 1 to 5 · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | 7 studies · 327 participants | Very low |
Low‐level laser therapy vs ultrasound Adverse events · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy vs fascial manipulation Overall improvement in CTS: SSS: short term (< 3 months) Scale from: 1 to 5 · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | 1 study · 70 participants | Very low |
Low‐level laser therapy vs fascial manipulation Overall improvement in CTS:SSS: long term ‐ not reported · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy vs fascial manipulation Overall improvement in CTS: FSS: short term (< 3 months) Scale from: 1 to 5 · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | 1 study · 70 participants | Very low |
Low‐level laser therapy vs fascial manipulation Overall improvement in CTS: FSS: long term · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy vs fascial manipulation Adverse events · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy and a splint vs ultrasound and a splint Overall improvement in CTS:SSS: short term (< 3 months) Scale from: 1 to 5 · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | 1 study · 66 participants | Very low |
Low‐level laser therapy and a splint vs ultrasound and a splint Overall improvement in CTS:SSS: long term ‐ not measured · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy and a splint vs ultrasound and a splint Overall improvement in CTS: FSS: short term (< 3 months) Scale from: 1 to 5 · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | 1 study · 66 participants | Very low |
Low‐level laser therapy and a splint vs ultrasound and a splint Overall improvement in CTS: FSS: long term ‐ not reported · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy vs placebo Overall improvement in CTS: SSS: long term Scale from: 1 to 5 · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | 1 study · 25 participants | Very low |
Low‐level laser therapy and a splint vs ultrasound and a splint Adverse events · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy and a splint vs placebo and a splint Overall improvement in CTS: SSS: short term (< 3 months) Scale from: 1 to 5 · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | 1 study · 112 participants | Very low |
Low‐level laser therapy and a splint vs placebo and a splint Overall improvement in CTS: SSS: long term ‐ not measured · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy and a splint vs placebo and a splint Overall improvement in CTS: FSS: short term (< 3 months) Scale from: 1 to 5 · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | 1 study · 112 participants | Very low |
Low‐level laser therapy and a splint vs placebo and a splint Overall improvement in CTS: FSS: long term ‐ not measured · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy and a splint vs placebo and a splint Adverse events · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | RR 2 [0.38, 10.48] | 1 study · 112 participants | Very low |
Low‐level laser therapy, wrist splint, and vitamin B6 vs placebo, wrist splint, and vitamin B6 Overall improvement in CTS: SSS: short term (< 3 months) Scale unknown · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | 1 study · 33 participants | Very low |
Low‐level laser therapy, wrist splint, and vitamin B6 vs placebo, wrist splint, and vitamin B6 Overall improvement in CTS: SSS: long term ‐ not measured · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy, wrist splint, and vitamin B6 vs placebo, wrist splint, and vitamin B6 Overall improvement in CTS: FSS: short term (< 3 months) Scale not known · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | 1 study · 33 participants | Very low |
Low‐level laser therapy, wrist splint, and vitamin B6 vs placebo, wrist splint, and vitamin B6 Overall improvement in CTS: FSS: long term ‐ not reported · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy vs placebo Overall improvement in CTS: FSS: short term (< 3 months) Scale from: 1 to 5 · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | 5 studies · 159 participants | Very low |
Low‐level laser therapy, wrist splint, and vitamin B6 vs placebo, wrist splint, and vitamin B6 Adverse events · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy vs placebo Overall improvement in CTS: FSS: long term Scale from: 1 to 5 · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | 1 study · 25 participants | Very low |
Low‐level laser therapy vs placebo Adverse events · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy vs ultrasound Overall improvement in CTS: SSS: short term (< 3 months) Scale from: 1 to 5 · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | 2 studies · 127 participants | Very low |
Low‐level laser therapy vs ultrasound Overall improvement in CTS: SSS: long term Scale from: 1 to 5 · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | 1 study · 27 participants | Very low |
Low‐level laser therapy vs ultrasound Overall improvement in CTS: FSS: short term (< 3 months) Scale from: 1 to 5 · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | 2 studies · 127 participants | Very low |
Low‐level laser therapy vs ultrasound Overall improvement in CTS: FSS: long term Scale from: 1 to 5 · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | 1 study · 27 participants | Very low |
Corticosteroid vs control Disability grade change after 4 weeks GBS disability grade. Scale from: 0 to 6 · people with Guillain‐Barré syndrome Corticosteroids for Guillain‐Barré syndrome (2016) · Cochrane | no estimate extracted | 6 studies · 587 participants | Moderate |
Corticosteroid vs control Disability grade change after 4 weeks ‐ oral regimens GBS disability grade. Scale from: 0 to 6 · people with Guillain‐Barré syndrome Corticosteroids for Guillain‐Barré syndrome (2016) · Cochrane | no estimate extracted | 4 studies · 120 participants | Very low |
Corticosteroid vs control Disability grade change after 4 weeks ‐ intravenous regimens GBS disability grade. Scale from: 0 to 6 · people with Guillain‐Barré syndrome Corticosteroids for Guillain‐Barré syndrome (2016) · Cochrane | no estimate extracted | 2 studies · 467 participants | Moderate |
Corticosteroid vs control Improvement by ≥ 1 grades after 4 weeks GBS disability grade scale · people with Guillain‐Barré syndrome Corticosteroids for Guillain‐Barré syndrome (2016) · Cochrane | RR 1.08 [0.93, 1.24] | 5 studies · 567 participants | Moderate |
Corticosteroid vs control Death or disability after 1 year · people with Guillain‐Barré syndrome Corticosteroids for Guillain‐Barré syndrome (2016) · Cochrane | RR 1.51 [0.91, 2.5] | 3 studies · 491 participants | Moderate |